Lv1
30 积分 2025-08-14 加入
[Chinese expert consensus on the diagnosis and management of nodal peripheral T-cell lymphoma (2025)]
7个月前
已完结
FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T‐CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION (SGN35‐032, TRIAL IN PROGRESS)
9个月前
已完结
The Short-Term Efficacy and Safety of Brentuximab Vedotin Chemotherapy Combined with Chidamide in the Treatment of CD30-Positive Peripheral T-Cell Lymphoma
9个月前
已关闭
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study
9个月前
已完结
Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell Lymphoma
1年前
已完结
Clinical Experience With Brentuximab Vedotin in Treating Cutaneous T‐Cell Lymphoma: A Retrospective Review From China
1年前
已完结
皖公网安备34019202002308
